Securities code: Guangzhou Wondfo Biotech Co.Ltd(300482) securities abbreviation: Guangzhou Wondfo Biotech Co.Ltd(300482) Announcement No.: 2022022 bond Code: 123064 bond abbreviation: Wanfu convertible bond
Guangzhou Wondfo Biotech Co.Ltd(300482)
Clarification Announcement on media reports
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Hearsay situation
Recently, Guangzhou Wondfo Biotech Co.Ltd(300482) (hereinafter referred to as "the company") was concerned about the media release entitled "the first batch of antigen test kits in Dashenlin Pharmaceutical Group Co.Ltd(603233) Shenzhen stores have not arrived Guangzhou Wondfo Biotech Co.Ltd(300482) 19.3 yuan / time", "covid-19 antigen self-test products are delayed on the shelves? Or relevant qualifications need to be supplemented" "Exclusive Dashenlin Pharmaceutical Group Co.Ltd(603233) and Guangzhou Wondfo Biotech Co.Ltd(300482) signed a strategic cooperation agreement on the sales of covid-19 antigen self-test reagent", "covid-19 can also be tested at home, and the results will be obtained in 15 minutes! Lbx Pharmacy Chain Joint Stock Company(603883) large pharmacies will soon be the first batch to be sold...", According to these reports, " Dashenlin Pharmaceutical Group Co.Ltd(603233) all employees have sent a circle of friends about the upcoming sale of antigen detection reagents", " Dashenlin Pharmaceutical Group Co.Ltd(603233) and Guangzhou Wondfo Biotech Co.Ltd(300482) have signed a strategic cooperation agreement on the distribution of covid-19 antigen self-test reagents, and Guangzhou Wondfo Biotech Co.Ltd(300482) covid-19 antigen self-test reagents will be 'launched' in Dashenlin Pharmaceutical Group Co.Ltd(603233) offline stores tomorrow" "At present, Guangzhou Wondfo Biotech Co.Ltd(300482) because there is no instruction for replacing antigen detection reagent, it has been required to temporarily take off the shelf in OTC channel and re put on the shelf after replacing the product instruction". " Lbx Pharmacy Chain Joint Stock Company(603883) pharmacy has reached cooperation with Guangzhou Guangzhou Wondfo Biotech Co.Ltd(300482) pharmacy. The first batch of covid-19 antigen rapid test products have been in the process of logistics and transportation and are expected to be put on shelves in stores in the near future".
2、 Clarification
At present, for the company, it is the overriding task to make every effort to meet the needs of epidemic prevention and control and provide support for epidemic prevention and control. The company attaches great importance to the above situation. After verification, the company now explains the relevant matters as follows:
1. The New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method) developed by the company was approved by the State Administration of drug administration in November 3, 2020 to issue the medical device registration certificate (National weapon registration 20203400830) and the medical device approval document was changed in March 12, 2022. After the change of the above-mentioned medical device approval documents, the company is preparing the production materials before going online according to the approved medical device change registration (filing) documents. As of the date of this announcement, no antigen detection reagent products after the change of registration certificate have been put on the market.
2, as of the date of this announcement, the company has not yet reached a sales agreement with the commercial New Coronavirus retail OTC channel on the Guangzhou Wondfo Biotech Co.Ltd(300482) New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method), which has changed the registration certificate in March 12th, and has not yet sold such products.
3、 Other instructions
1. The company will continue to fulfill the obligation of information disclosure in strict accordance with the provisions and requirements of relevant laws and regulations, and do a good job of information disclosure in a timely manner.
2, the company reserves the right to pursue legal liability for any products and individuals who have been authorized by the company to claim the products of New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold) developed by the company.
3. Securities times, China Securities News, Securities Daily, Shanghai Securities News and cninfo (www.cn. Info. Com. CN.) The information disclosure media designated by the CSRC is the information disclosure media selected by the company. All information of the company shall be subject to the information published in the above designated media. Investors are invited to invest rationally and pay attention to risks.
It is hereby announced.
Guangzhou Wondfo Biotech Co.Ltd(300482) board of directors March 14, 2022
